Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: stapled peptide therapeutics - Rein Therapeutics/Roche

Next Previous
Drug Profile

Research programme: stapled peptide therapeutics - Rein Therapeutics/Roche

Alternative Names: ATSP-7041; MDM2/MDMX dual inhibitor for p53-dependent cancers - Rein Therapeutics/Roche

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aileron Therapeutics; Roche
  • Developer Rein Therapeutics; Roche
  • Class Peptides
  • Mechanism of Action Protein modulators; Proto-oncogene protein c-mdm2 inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported CNS disorders; Haematological malignancies; Inflammation; Metabolic disorders; Solid tumours; Viral infections

Most Recent Events

  • 10 Jan 2025 Aileron Therapeutics is now called Rein Therapeutics
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top